home.social

#biogen — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #biogen, aggregated by home.social.

  1. Why did Biogen pay up for Apellis Pharmaceuticals?

    Because this may be less about buying a drug and more about buying a nephrology platform.

    Our latest argues that kidney disease is starting to look like biotech’s next strategic battleground, and that Biogen’s Apellis deal may be an early signal of where the industry is heading.

    Read more: biotech.industryexaminer.com/b

    #Biotech #KidneyDisease #Nephrology #Biogen #TechNews

  2. Zimmer Biomet ($ZBH) reported EPS of $1.74, matching the forecast of $1.74. Revenue was $1.82B, slightly exceeding the expected $1.8B.

    Global Payments ($GPN) achieved EPS of $3.08, just below the forecast of $3.09. Revenue reached $2.6B, surpassing the anticipated $2.38B.

    Biogen ($BIIB) posted EPS of $4.08, exceeding the forecast of $3.77. Revenue was $2.47B, slightly above the expected $2.43B.

    #Earnings #Q3 #ZimmerBiomet #GlobalPayments #Biogen #Investing #Finance #Stocks #MarketNews

  3. Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. japantimes.co.jp/news/2024/09/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain

  4. Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  5. Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B—Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset —9 top biopharma CEO-to-employee pay gaps --bit.ly/w28kSd #biogen #mergersandacquisitions #boehringeringelheim #cardiovasculardisease #pharmaceos #executivecompensation #paygap #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  6. J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  7. J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  8. J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  9. J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  10. Novo Nordisk owner buys majority stake in Austrian life science tools company—As sales of weight loss drugs skyrocket, the insulin market falters —Eisai starts rolling submission for injectable version of Alzheimer's drug with FDA --bit.ly/w28kSd #novonordisk #mergersandacquisitions #insulin #diabetes #alzheimers #eisai #biogen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  11. About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows—Biogen cost cuts drive profit beat, Alzheimer's drug sales jump —Enter Xaira, with $1bn for its AI in drug discovery platform--bit.ly/w28kSd #medicare #wegovy #novonordisk #biogen #earnings #drugdiscovery #ai #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  12. Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. japantimes.co.jp/news/2024/04/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us

  13. Biogen and Eisai fall behind on Leqembi’s subcutaneous BLA for Alzheimer’s—Teva, Viatris win new chance to challenge J&J schizophrenia drug patent—3M spins out Solventum--bit.ly/w28kSd #biogen #eisai #alzehimers #teva #jnj #patents #schizophrenia #3m #spinoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  14. Cancer and neuroscience led 2023 VC, M&A investment in biopharma—Biogen gets DOJ subpoena on business operations in foreign countries — GSK still has a crush on oligonucleotides, sealing the deal with Elsie--bit.ly/w28kSd #cancer #neuroscience #funding #venturecapital #biogen #doj #gsk #oligonucleotides #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  15. Cancer and neuroscience led 2023 VC, M&A investment in biopharma—Biogen gets DOJ subpoena on business operations in foreign countries — GSK still has a crush on oligonucleotides, sealing the deal with Elsie--bit.ly/w28kSd #cancer #neuroscience #funding #venturecapital #biogen #doj #gsk #oligonucleotides #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  16. Cancer and neuroscience led 2023 VC, M&A investment in biopharma—Biogen gets DOJ subpoena on business operations in foreign countries — GSK still has a crush on oligonucleotides, sealing the deal with Elsie--bit.ly/w28kSd #cancer #neuroscience #funding #venturecapital #biogen #doj #gsk #oligonucleotides #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  17. An expected news from Alzheimer therapies, alzforum.org/news/community-ne

    A bit nostalgic, though, because I was one of the few whose cognition improved (relatively, i.e. compared to the control-group) during the years I got the antibody 10 mg / kg, enough for Biogen to apply for license.

    It was a marvellous box-seat to observe pharmaceutical research with all it's intricacies, and live neurological expertise within an arm's reach was invaluable.

    Here is the history of aducanumab, rest in pieces, alzforum.org/therapeutics/aduh

    #alzheimers #aducanumab #aduhelm #biogen

  18. Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal - Enlarge / The exterior of the headquarters of biotechnology company Bio... - arstechnica.com/?p=2000435 #clinicaltrial #aducanumab #alzheimers #science #aduhelm #health #biogen #fda

  19. New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. japantimes.co.jp/news/2023/12/ #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals

  20. As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches-- Bayer CEO Anderson says 'radical realignment' is underway --Gilead tumbles after unpredictable element drove its 3Q beat -- See more on our front page news bit.ly/w28kSd #biogen #pharmaceos #bayer #layoffs #gileadsciences #earnings #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  21. As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches-- Bayer CEO Anderson says 'radical realignment' is underway --Gilead tumbles after unpredictable element drove its 3Q beat -- See more on our front page news bit.ly/w28kSd #biogen #pharmaceos #bayer #layoffs #gileadsciences #earnings #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  22. Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  23. Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  24. Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  25. Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  26. Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  27. quote :
    厚生勞動省(相當於衛生福利部)專家小組8月21日審核通過 #日本 #衛采製藥#Eisai )與 #美國 藥廠 #百健#Biogen )合作開發的 #阿茲海默症 新藥 #Lecanemab (又稱為 #Leqembi )。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

    cna.com.tw/news/aopl/202309250

  28. quote :
    厚生勞動省(相當於衛生福利部)專家小組8月21日審核通過 #日本 #衛采製藥#Eisai )與 #美國 藥廠 #百健#Biogen )合作開發的 #阿茲海默症 新藥 #Lecanemab (又稱為 #Leqembi )。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

    cna.com.tw/news/aopl/202309250

  29. quote :
    厚生勞動省(相當於衛生福利部)專家小組8月21日審核通過 #日本 #衛采製藥#Eisai )與 #美國 藥廠 #百健#Biogen )合作開發的 #阿茲海默症 新藥 #Lecanemab (又稱為 #Leqembi )。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

    cna.com.tw/news/aopl/202309250

  30. quote :
    厚生勞動省(相當於衛生福利部)專家小組8月21日審核通過 #日本 #衛采製藥#Eisai )與 #美國 藥廠 #百健#Biogen )合作開發的 #阿茲海默症 新藥 #Lecanemab (又稱為 #Leqembi )。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

    cna.com.tw/news/aopl/202309250

  31. quote :
    厚生勞動省(相當於衛生福利部)專家小組8月21日審核通過 #日本 #衛采製藥#Eisai )與 #美國 藥廠 #百健#Biogen )合作開發的 #阿茲海默症 新藥 #Lecanemab (又稱為 #Leqembi )。日本厚生勞動大臣武見敬三今天正式批准這種新藥。

    cna.com.tw/news/aopl/202309250

  32. Moderna, Regeneron post solid earnings, eye a strong finish to 2023 -- Sarepta offers early look at closely watched gene therapy launch -- Biogen looks at selling biosims unit to longtime ally Samsung Bioepis -- See more on our front page news bit.ly/w28kSd #earnings #moderna #regeneron #sarepta #dmd #genetherapy #biogen #biosimilars #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  33. Moderna, Regeneron post solid earnings, eye a strong finish to 2023 -- Sarepta offers early look at closely watched gene therapy launch -- Biogen looks at selling biosims unit to longtime ally Samsung Bioepis -- See more on our front page news bit.ly/w28kSd #earnings #moderna #regeneron #sarepta #dmd #genetherapy #biogen #biosimilars #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  34. Sage's new #antidepressant is more like an antibiotic than an SSRI: it's taken for 14 days, then re-dosed as needed. But its long-term effectiveness is debatable.

    Turns out, it's so rapid-acting that some psychiatrists don't even care. But will the #FDA?

    My preview ahead of the FDA decision:
    www.statnews.com/2023/07/31/sage-zuranolone-antidepressant-fda/

    #depression #sage #biogen #ssri #health #mentalhealth #healthcare #medicine #biotech #pharma

  35. Pfizer, Flagship join forces to hunt for 10 new drugs—Four crucial questions about the Humira biosimilar price war -- Medicare's proposed coverage for Alzheimer's scan could be boon for Eisai and Biogen -- See more on our front page news bit.ly/w28kSd #pfizer #flagshippioneering #humira #abbvie #drugdevelopment #alzheimers #biosimilar #medicare #cms #biogen #eisai #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  36. Pfizer, Flagship join forces to hunt for 10 new drugs—Four crucial questions about the Humira biosimilar price war -- Medicare's proposed coverage for Alzheimer's scan could be boon for Eisai and Biogen -- See more on our front page news bit.ly/w28kSd #pfizer #flagshippioneering #humira #abbvie #drugdevelopment #alzheimers #biosimilar #medicare #cms #biogen #eisai #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  37. Four senior #FDA leaders forged close ties with #Biogen ahead of #Aduhelm's approval. Now they've all left FDA. Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers
    endpts.com/four-senior-fda-lea #revolvingdoor #quidproquo

  38. FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)

    The Foo... - arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda